Lowest Price Guaranteed From USD 799
Published
March 2016
Slides
Not Available
View Count
3771
Example Insights
Available on request
Report Description
Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for two or three different epitopes concurrently.
Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. As of now, only two bsAbs, Removab and Blincyto, have been approved and are available in the market. The focus of the pipeline drugs is on oncology as well as on non-oncological indications such as rheumatoid arthritis and other inflammatory diseases.
The primary objective of this report is to capture details on the various clinical and preclinical trials which are currently underway in the field of bsAb therapeutics.We have identified a number of such trials which are taking place for a variety of indications across multiple geographies.For each specific trial, we have provided the following information:
Trial Objective
Manufacturer /Licensee
Technology
Target Antigen
Indication
Sponsor / Collaborator
Trial Phase
Trial Status
Start Date
End Date
Enrolment
AgeGroup
Inclusion Criteria
Exclusion Criteria
StudyDesign
PrimaryEndpoint
SecondaryEndpoint
Treatment Arms
Route ofAdministration
Location(s)
Trial Results (if known)
The above information has also been presented in the form a dashboard to provide a high level quick overview of the ongoing activity in this space.
In addition to the clinical trial details, the report also provides the following:
Sales forecasts of the bispecific antibody market over the course of next ten years. Owing to the niche nature of this market, we have presented three scenarios to add robustness to our market forecast. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.
Industry SWOT analysis summarising the challenges as well as opportunities in the market for different stakeholders.
Contents
Introduction and Pipeline Details
1.Market Overview
2.Dashboard: Pipeline Analysis
3.Molecules in Clinical Development: Trial Details
4.Molecules in Preclinical Development: Trial Details
5.Inclusion / Exclusion Criteria
Market Forecast, 2014 - 2024
6.Market Forecast: Comparative Scenarios
Industry Analysis
7.Industry SWOT Analysis
Pipeline Details
Figure 1 Bispecific Antibodies in Clinical Development: Distribution by Companies
Figure 2 Bispecific Antibodies in Clinical Development: Distribution by Highest Phase of Development
Figure 3 Bispecific Antibodies in Clinical Development: Distribution by Type of Bispecific System
Figure 4 Bispecific Antibodies in Clinical Development: Distribution by Indication
Figure 5 Bispecific Antibodies Clinical Trials: Distribution by Trial Phase and Status (Matrix View)
Figure 6 Bispecific Antibodies Clinical Trials: Distribution by Trial Status
Figure 7 Bispecific Antibodies Clinical Trials: Distribution by Trial Phase
Figure 8 Bispecific Antibodies Clinical Trials: Distribution by Indication
Figure 9 Bispecific Antibodies Clinical Trials: Distribution by Sponsor Type
Figure 10 Bispecific Antibodies Clinical Trials: Distribution by Region
Figure 11 Bispecific Antibodies Clinical Trials: Distribution by Molecules and Countries (Matrix View)
Figure 12 Bispecific Antibodies Clinical Trials: Distribution by G7 Countries
Figure 13 Bispecific Antibodies Clinical Trials: Distribution by EU5 Countries
Figure 14 Bispecific Antibodies in Preclinical Development: Distribution by Indication
Market Forecast Analysis
Figure A Bispecific Antibody Therapeutics Market Forecast, Scenario Comparison (USD MM)
Pipeline Details
Table 1 Molecules in Clinical Development: Pipeline Details
Table 2 Molecules in Preclinical Development: Pipeline Details
Industry Analysis
Table 3 SWOT Analysis
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES